Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2015 1
2016 2
2017 1
2018 1
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema.
Campochiaro PA, Peters KG. Campochiaro PA, et al. Curr Diab Rep. 2016 Dec;16(12):126. doi: 10.1007/s11892-016-0816-5. Curr Diab Rep. 2016. PMID: 27778249 Review.
In two clinical trials in diabetic macular edema (DME) patients, subcutaneous injections of AKB-9778 were safe and provided added benefit to VEGF suppression. Preliminary data suggest that AKB-9778 monotherapy improves diabetic retinopathy. Thes …
In two clinical trials in diabetic macular edema (DME) patients, subcutaneous injections of AKB-9778 were safe and prov …
Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapies.
Miller K, Fortun JA. Miller K, et al. Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):28-35. doi: 10.22608/APO.2017529. Asia Pac J Ophthalmol (Phila). 2018. PMID: 29473719 Review.
Diabetic retinopathy and diabetic macular edema comprise a major source of visual disability throughout the developed world. ...Our knowledge of diabetic macular edema continues to grow, leading to new currently available an
Diabetic retinopathy and diabetic macular edema comprise a major source of visual disability throughout t
Diabetic macular oedema.
Tan GS, Cheung N, Simó R, Cheung GC, Wong TY. Tan GS, et al. Lancet Diabetes Endocrinol. 2017 Feb;5(2):143-155. doi: 10.1016/S2213-8587(16)30052-3. Epub 2016 Aug 3. Lancet Diabetes Endocrinol. 2017. PMID: 27496796 Review.
Diabetic macular oedema, characterised by exudative fluid accumulation in the macula, is the most common form of sight-threatening retinopathy in people with diabetes. ...Emerging therapeutic strategies include improving efficacy and duration of VEGF s
Diabetic macular oedema, characterised by exudative fluid accumulation in the macula, is the most common form of sight-threate
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.
Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Hussain RM, et al. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. doi: 10.1080/13543784.2019.1667333. Epub 2019 Sep 26. Expert Opin Investig Drugs. 2019. PMID: 31513439 Review.
Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). ...AKB-9778 monotherapy did not reduce diabetic reti
Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular
Molecular pathogenesis of retinal and choroidal vascular diseases.
Campochiaro PA. Campochiaro PA. Prog Retin Eye Res. 2015 Nov;49:67-81. doi: 10.1016/j.preteyeres.2015.06.002. Epub 2015 Jun 23. Prog Retin Eye Res. 2015. PMID: 26113211 Free PMC article. Review.
Most prevalent of these are diabetic retinopathy and retinal vein occlusions. Subretinal and choroidal NV occur in diseases of the outer retina and Bruch's membrane, the most prevalent of which is age-related macular degeneration. ...Neutralization of …
Most prevalent of these are diabetic retinopathy and retinal vein occlusions. Subretinal and choroidal NV occur in diseases of …
A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling.
Mirando AC, Shen J, Silva RLE, Chu Z, Sass NC, Lorenc VE, Green JJ, Campochiaro PA, Popel AS, Pandey NB. Mirando AC, et al. JCI Insight. 2019 Feb 21;4(4):e122043. doi: 10.1172/jci.insight.122043. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30668550 Free PMC article.
The potentiation of Tie2 activation by Ang2 even extended to mouse models in which AXT107 induced Tie2 phosphorylation in a model of hypoxia and inhibited vascular leakage in an Ang2-overexpression transgenic model and an LPS-induced inflammation model. Because Ang2 …
The potentiation of Tie2 activation by Ang2 even extended to mouse models in which AXT107 induced Tie2 phosphorylation in a mo …
Ocular neovascularisation and excessive vascular permeability.
Campochiaro PA. Campochiaro PA. Expert Opin Biol Ther. 2004 Sep;4(9):1395-402. doi: 10.1517/14712598.4.9.1395. Expert Opin Biol Ther. 2004. PMID: 15335307 Review.
Signalling through the VEGF pathway is modulated by the Tie2 receptor and its binding partners, the angiopoietins. Each of the participants in these two signalling pathways provides a potential target for intervention. ...
Signalling through the VEGF pathway is modulated by the Tie2 receptor and its binding partners, the angiopoietins. Each of the partic …
Feedback